Today’s AI Top Pick: GEN
9/30/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.
AI-ranked from a screened shortlist, with entry strategy, targets, and risks.
View the live GEN price forecast →
Gen Digital (GEN) is the best risk/reward dip-buy right now because it uniquely combines a deep, exhausted drawdown with multi-timeframe confirmation and genuine fundamental quality — a combination no other candidate in the pool fully delivers. The stock fell -31.97% over the last 14 days with an RSI of 19.4, signaling oversold exhaustion rather than a broken trend. Critically, the 1-hour timeframe shows the stock has stabilized at the top of its 21-bar range (pos_in_21bar_range_pct = 77.67) with a modest -0.92% drawdown from the 21-bar high — a clear sign selling pressure has dried up. The 1-day and 1-week timeframes both show the stock sitting near the lows of its range (2.25% and 0% respectively) with strong positive forecasts in the mid (25.61%) and long (12.68%) horizons on the daily, and a bullish_prob of 1.0 with near_term_bullish of 1.0. This is textbook exhaustion: the stock has stopped making fresh lows on the short timeframe while offering upside potential on the longer horizons. The fundamentals support the thesis and distinguish GEN from the speculative biotech and small-cap names in the pool. It trades at a P/E of 12.1 with a forward P/E of just 6.3, a PEG of 0.52, a ROE of 41.94%, and a profit margin of 20.73%. Analyst support is solid with a recommendation of 2.38 (moderate buy) and a target upside of 60.7%. The fundamental_score of 8 is the highest in the pool. Recent headlines are constructive: Gen Digital affirmed its FY2027 EPS guidance of $2.87-$2.97 and Q2 guidance above estimates, with outlook tracking at the high end of guidance. Zacks noted a potential trend reversal after the 32.7% drop. This is not a broken trend chasing a speculative bounce — it's a quality company with profitable operations, reasonable valuation, and analyst backing that has been oversold. Today is the right entry because the multi-timeframe signals are aligned and the stock has shown stability on the short timeframe after the decline. Waiting risks missing the bounce if momentum continues to turn positive, but the risk is contained given the oversold conditions and fundamental support. The combination of exhausted selling on the 1-hour, positive forecasts on the daily and weekly, and solid fundamentals makes GEN the highest-conviction pick in the pool.
- Sector concentration risk: Technology sector exposure during any market-wide tech selloff
- The -31.97% drawdown could continue if broader market conditions deteriorate
- Forward P/E of 6.3 implies high expectations that must be met
- Institutional ownership of 93.75% means potential for sharp moves on institutional rebalancing
- Short float of 6.56% provides some support but limited short-seller buying pressure
| # | Symbol | Verdict | Score | Read |
|---|---|---|---|---|
| 1 | GEN | BUY NOW | 9.5 | Quality company with exhausted selling, multi-timeframe confirmation, and solid fundamentals — highest conviction pick. |
| 2 | GSHD | BUY PULLBACK | 8.0 | Strong technical setup and reasonable valuation, but new leadership creates uncertainty. |
| 3 | AN | BUY PULLBACK | 7.5 | Attractive fundamentals and oversold conditions, but high debt and weak performance create caution. |
| 4 | MNDY | WAIT | 7.0 | Good fundamentals (P/E 32.42, PEG 0.53) but recent sharp decline and negative margins create uncertainty. |
| 5 | NCNO | WAIT | 6.5 | Reasonable valuation (P/E 59.5, PEG 0.59) but weak profitability and negative performance. |
| 6 | NEOV | WAIT | 6.0 | High growth potential (sales YoY 58.22%) but negative margins and early-stage company. |
| 7 | DKNG | WAIT | 5.5 | Strong brand and growth but negative margins and recent decline create uncertainty. |
| 8 | ENLV | WAIT | 5.0 | Extreme drawdown (-95% YTD) with speculative setup and no fundamentals coverage. |
| 9 | PDSB | WAIT | 4.5 | Positive clinical data but financing scrutiny and weak technicals. |
| 10 | TVRD | WAIT | 4.0 | Positive preclinical data but early-stage and speculative. |
| 11 | BCDA | WAIT | 3.5 | FDA catalysts positive but stock fell 10% after hours and weak fundamentals. |
| 12 | CABA | WAIT | 3.0 | Positive conference activity but negative margins and early-stage company. |
| 13 | ATRA | WAIT | 2.5 | Early-stage biotech with negative margins and weak performance. |
| 14 | LUMN | WAIT | 2.0 | Exchange move to Nasdaq neutral but negative margins and weak performance. |
| 15 | RILY | WAIT | 1.5 | Acquisition catalyst positive but small cap and speculative. |
| 16 | XENE | WAIT | 1.0 | Positive news flow but negative margins and early-stage company. |
| 17 | ONT | WAIT | 0.5 | Positive business momentum but negative margins and weak technicals. |
| 18 | WALD | AVOID | 0.0 | Negative earnings, sales miss, and delisting create significant risk. |
| 19 | RCKT | WAIT | -0.5 | FDA alignment positive but negative margins and early-stage company. |
| 20 | LXEO | WAIT | -1.0 | Positive M&A activity but negative margins and early-stage company. |
| 21 | RIME | AVOID | -1.5 | Dilutive financing terminated but weak fundamentals and speculative. |
| 22 | BEEM | WAIT | -2.0 | Acquisition catalyst positive but negative margins and early-stage company. |
| 23 | TYGO | WAIT | -2.5 | Positive business momentum but weak guidance and analyst cuts. |
Get AI top picks & forecasts on any stock
K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord